• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Robin Shah: Biosimilars in Community Oncology


Robin Shah, chief commercial officer of OneOncology, addresses the role that biosimilars have in community oncology.


We're really excited about some of the shifts in biosimilars. And this comes from a number of things. The first is the advancement of science in this space really is going to pave the future for opportunities for new drug classes to come into community oncology and oncology in general.

The second is, as we go into value-based arrangements, the important thing that comes with value-based is total cost of care. And with the introduction of biosimilars and a lot of the new relationships that OneOncology is going into, we're going to really be able to reduce the total cost of care with all these new agents being introduced to the marketplace.

And as you may have seen from our press release, we've gone into a large partnership on this front. And with the technology that we have, we can now really track and identify where we're complying with biosimilars, and where there are opportunities to shift some of our existing drug agents to new therapies that are coming out.

Related Videos
Jeffrey Casberg, RPh, MS.
Adam Colborn, JD.
Legal scale weighs profit as greater than medical treatment
Ha Kung Wong, JD.
Ha Kung Wong, JD
Cencora's Corey Ford
Brian Biehn
Chelsee Jensen, PharmD, BCPS
Ryan Haumschild, PharmD, MS, MBA
Related Content
© 2024 MJH Life Sciences

All rights reserved.